Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Free Radical Biology & Medicine

• Publication date

  2011-04-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.freeradbiomed.2011.01.001PMID 21236335
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines.

  2010cited by this paper
• Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis.

  2009cited by this paper
• High-Throughput Cell-Based Screening of 4910 Known Drugs and Drug-like Small Molecules Identifies Disulfiram as an Inhibitor of Prostate Cancer Cell Growth

  2009cited by this paper
• Lysosomal ceramide mediates gemcitabine-induced death of glioma cells

  2009cited by this paper
• Ceramide Regulates Gemcitabine-Induced Senescence and Apoptosis in Human Pancreatic Cancer Cell Lines

  2009cited by this paper
• Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.

  2007cited by this paper
• Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.

  2007cited by this paper
• Molecular consequences of SOD2 expression in epigenetically silenced pancreatic carcinoma cell lines

  2007cited by this paper
• Treatment of advanced pancreatic cancer.

  2007cited by this paper
• Increased stability of P21(WAF1/CIP1) mRNA is required for ROS/ERK-dependent pancreatic adenocarcinoma cell growth inhibition by pyrrolidine dithiocarbamate.

  2006cited by this paper
• Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation

  2006cited by this paper
• Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo

  2006cited by this paper
• Disulfiram, an old drug with new potential therapeutic uses for human cancers and fungal infections.

  2005cited by this paper
• Controlling tumor growth by modulating endogenous production of reactive oxygen species.

  2005cited by this paper
• Superoxide dismutases in malignant cells and human tumors.

  2004cited by this paper
• ROS stress in cancer cells and therapeutic implications.

  2004cited by this paper
• Pancreatic cancer

  2004cited by this paper
• Does disulfiram have a role in alcoholism treatment today?

  2004cited by this paper
• Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.

  2004cited by this paper
• Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines

  2003cited by this paper
• Adjuvant therapy in pancreatic cancer: historical and current perspectives.

  2003cited by this paper
• Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram.

  2003cited by this paper
• Genetic profile of 22 pancreatic carcinoma cell lines

  2001cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Direct Effect of Ceramide on the Mitochondrial Electron Transport Chain Leads to Generation of Reactive Oxygen Species

  1997cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper
• The actions of metabolic fate of disulfiram.

  1981cited by this paper
• The Actions and Metabolic Fate of Disulfiram

  1981cited by this paper

• Study of synergistic tumor toxicity in pancreatic cancer cells through liposomal drug combination therapy

  2026cites this paper
• Zinc ion-coordinated high-drug-loading nanoparticles for enhanced anti-tumor therapy

  2025cites this paper
• Exploring novel strategies to improve anti-tumour efficiency: The potential for targeting reactive oxygen species

  2023cites this paper
• High-capacity glycol chitosan-based nanoemulsion for efficient delivery of disulfiram.

  2023cites this paper
• Repurposing disulfiram as a chemo-therapeutic sensitizer: molecular targets and mechanisms.

  2022cites this paper
• A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker

  2021cites this paper
• COP9 signalosome is an essential and druggable parasite target that regulates protein degradation

  2020cites this paper
• MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.

  2020cites this paper
• Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes.

  2019cites this paper
• Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy

  2019cites this paper
• Targeting ALDH2 with disulfiram/copper reverses the resistance of cancer cells to microtubule inhibitors

  2018cites this paper
• Procyanidin B2 3,3″‐di‐O‐gallate induces oxidative stress‐mediated cell death in prostate cancer cells via inhibiting MAP kinase phosphatase activity and activating ERK1/2 and AMPK

  2018cites this paper
• Physicochemical Properties, Antioxidant and Cytotoxic Activities of Crude Extracts and Fractions from Phyllanthus amarus

  2017cites this paper
• Cell cycle specific radiosensitisation by the disulfiram and copper complex

  2017cites this paper
• Nano-enabled disulfiram for cancer therapy

  2017cites this paper
• Metabolic Modification in Gastrointestinal Cancer Stem Cells: Characteristics and Therapeutic Approaches

  2016cites this paper
• The antioxidant uncoupling protein 2 stimulates hnRNPA2/B1, GLUT1 and PKM2 expression and sensitizes pancreas cancer cells to glycolysis inhibition.

  2016cites this paper
• Antioxidant Mechanisms and ROS-Related MicroRNAs in Cancer Stem Cells

  2015cites this paper
• Combination of 12-O-tetradecanoylphorbol-13-acetate with diethyldithiocarbamate markedly inhibits pancreatic cancer cell growth in 3D culture and in immunodeficient mice

  2015cites this paper
• Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner.

  2015cites this paper
• Investigation into the effects of zinc on the anti-breast cancer properties of disulfiram

  2015cites this paper
• Cancer Biology and Signal Transduction Metallothionein 1 G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy

  2014cites this paper
• Bovine seminal ribonuclease triggers Beclin1-mediated autophagic cell death in pancreatic cancer cells.

  2014cites this paper
• Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast Cancer

  2014cites this paper
• CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide

  2014cites this paper
• Metallothionein 1G and Zinc Sensitize Human Colorectal Cancer Cells to Chemotherapy

  2014cites this paper
• Smart pH-sensitive and temporal-controlled polymeric micelles for effective combination therapy of doxorubicin and disulfiram.

  2013cites this paper
• A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care

  2013cites this paper
• Aldehyde dehydrogenase and HSP90 co-localize in human glioblastoma biopsy cells.

  2013cites this paper
• Reversing the Intractable Nature of Pancreatic Cancer by Selectively Targeting ALDH-High, Therapy-Resistant Cancer Cells

  2013cites this paper
• Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.

  2012cites this paper
• Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine.

  2012cites this paper
• 327 Activating transcription factor 3 as a novel regulator and predictor of cisplatin response in human cancers

  2010cites this paper